Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mediscience nears tests for optical detector in US cervical cancer trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given Mediscience Technology the all-clear to begin a multicentre pilot trial of its cervical cancer detector, a fluorescence-based optical device called the Cancer Diagnostic-Ratiometer (CD-R). The study will aim to determine the device's efficacy at distinguishing between tissues that are normal, benign, precancerous low grade, precancerous high grade, carcinoma in situ and cancer; the device's real-time results will be compared with those for Pap tests and biopsies. It will also assess any adverse events. Last month, Cherry Hill, New Jersey-based Mediscience said that it had teamed up with New York firm Alfanix Technology to construct the CD-R and other photonics devices for cancer diagnostics, and to introduce the devices into Latin America for testing on humans.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel